ATE107515T1 - Zusammensetzung zur behandlung von entzündung. - Google Patents

Zusammensetzung zur behandlung von entzündung.

Info

Publication number
ATE107515T1
ATE107515T1 AT90850286T AT90850286T ATE107515T1 AT E107515 T1 ATE107515 T1 AT E107515T1 AT 90850286 T AT90850286 T AT 90850286T AT 90850286 T AT90850286 T AT 90850286T AT E107515 T1 ATE107515 T1 AT E107515T1
Authority
AT
Austria
Prior art keywords
inflammation
treatment
composition
antichymotrypsin
fowl
Prior art date
Application number
AT90850286T
Other languages
English (en)
Inventor
John Lezdey
Allan Wachter
Original Assignee
John Lezdey
Allan Wachter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Lezdey, Allan Wachter filed Critical John Lezdey
Application granted granted Critical
Publication of ATE107515T1 publication Critical patent/ATE107515T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT90850286T 1989-12-04 1990-08-29 Zusammensetzung zur behandlung von entzündung. ATE107515T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/445,005 US5008242A (en) 1986-12-24 1989-12-04 Treatment of inflammation using 1-antichymotrypsin

Publications (1)

Publication Number Publication Date
ATE107515T1 true ATE107515T1 (de) 1994-07-15

Family

ID=23767272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90850286T ATE107515T1 (de) 1989-12-04 1990-08-29 Zusammensetzung zur behandlung von entzündung.

Country Status (8)

Country Link
US (1) US5008242A (de)
EP (1) EP0432117B1 (de)
JP (1) JPH03181422A (de)
AT (1) ATE107515T1 (de)
CA (1) CA2019974C (de)
DE (1) DE69010162T2 (de)
DK (1) DK0432117T3 (de)
ES (1) ES2055406T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114917A (en) * 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US5674708A (en) * 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
US5723316A (en) * 1989-06-23 1998-03-03 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having chymase inhibiting activity
EP0512090B2 (de) * 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Behandlung von entzündungen
JPH067191A (ja) * 1991-09-26 1994-01-18 Konica Corp モノクローナル抗体、それを産生するハイブリド−マ、その対応抗原及びそれを用いた測定方法
US5422244A (en) * 1992-05-05 1995-06-06 Athena Neurosciences, Inc. Detection of brain α1-antichymotrypsin
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
EP0898962A1 (de) * 1997-08-28 1999-03-03 Becton, Dickinson and Company Transdermale Pflaster und Verfahren zur Inaktivierung von Hautproteasen
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
DE10121255A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
AU2002254999B2 (en) * 2001-04-30 2007-07-26 Bayer Innovation Gmbh Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
WO2004052236A2 (en) * 2002-12-06 2004-06-24 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
EP1660094A4 (de) * 2003-08-26 2009-09-16 Univ Colorado Hemmer der serinprotease-aktivität und ihre verwendung bei verfahren und zusammensetzungen zur behandlung von bakterieninfektionen
US7217690B2 (en) 2003-10-07 2007-05-15 Kimberly-Clark Worldwide, Inc. Compositions of sunflower trypsin inhibitors
AU2005221151A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US8852569B2 (en) * 2008-08-28 2014-10-07 The General Hospital Corporation Prevention and treatment of itch with cysteine protease inhibition
CA2839917A1 (en) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2016118632A1 (en) 2015-01-20 2016-07-28 The General Hospital Corporation Prevention and treatment of itch with an mrgpr antagonist
WO2021020509A1 (ja) * 2019-07-31 2021-02-04 株式会社ステムリム 間葉系幹細胞の増殖促進または減少抑制のための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin

Also Published As

Publication number Publication date
EP0432117A1 (de) 1991-06-12
DE69010162D1 (de) 1994-07-28
EP0432117B1 (de) 1994-06-22
DK0432117T3 (da) 1994-07-25
US5008242A (en) 1991-04-16
JPH03181422A (ja) 1991-08-07
ES2055406T3 (es) 1994-08-16
CA2019974C (en) 2002-01-22
CA2019974A1 (en) 1991-06-04
DE69010162T2 (de) 1994-10-06

Similar Documents

Publication Publication Date Title
ATE107515T1 (de) Zusammensetzung zur behandlung von entzündung.
PT93333A (pt) Processo de preparacao de uma composicao biocida sinergica e de tratamento usando a referida composicao
DE69019716D1 (de) Medizinisches Gerät zur Laserbehandlung.
DE3486235D1 (de) Fettsäure-Zusammensetzungen.
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
BR8804161A (pt) Composicao aperfeicoada esterilizavel por radiacao
DE68910799D1 (de) Faserbehandlungszusammensetzung.
DE69013999D1 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
DE3381624D1 (de) Mittel zur behandlung von wunden.
ATE195424T1 (de) Verfahren zur verbesserung der wundheilung und gewebeerneuerung
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
DE69000960D1 (de) Zusammensetzung zur behandlung von pigmentierung.
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
FI896031A7 (fi) Kasvinkäsittelykoostumus
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee